Complete Surgical Resection

Also known as: Complete resection

Drug	Drug Name	Drug Description
DB06186	Ipilimumab	A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
DB09035	Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DB08911	Trametinib	A kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer.

Drug	Drug Name	Target	Type
DB06186	Ipilimumab	Cytotoxic T-lymphocyte protein 4	target
DB09035	Nivolumab	Programmed cell death protein 1	target
DB09035	Nivolumab	Programmed cell death 1 ligand 1	target
DB08911	Trametinib	Cytochrome P450 2C8	enzyme
DB08911	Trametinib	Cytochrome P450 3A4	enzyme
DB08911	Trametinib	Dual specificity mitogen-activated protein kinase kinase 1	target
DB08911	Trametinib	Dual specificity mitogen-activated protein kinase kinase 2	target

Drug	Drug Name	Phase	Status	Count
DB00958	Carboplatin	2	Recruiting	1
DB00515	Cisplatin	2	Recruiting	1
DB00441	Gemcitabine	2	Recruiting	1
DB09035	Nivolumab	2	Recruiting	1
DB00642	Pemetrexed	2	Recruiting	1